.

BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Argus Health
Accenture
Daiichi Sankyo
Chubb
Federal Trade Commission
Baxter
McKesson
Mallinckrodt
Cerilliant
Johnson and Johnson

Generated: December 15, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 022272

« Back to Dashboard

NDA 022272 describes OXYCONTIN, which is a drug marketed by Purdue Pharma Lp and is included in one NDA. It is available from thirteen suppliers. There are twenty patents protecting this drug and seven Paragraph IV challenges. Additional details are available on the OXYCONTIN profile page.

The generic ingredient in OXYCONTIN is oxycodone hydrochloride. There are seventeen drug master file entries for this compound. Fifty-nine suppliers are listed for this compound. Additional details are available on the oxycodone hydrochloride profile page.

Summary for 022272

Tradename:1
Applicant:1
Ingredient:1
Patents:20
Therapeutic Class:Analgesics
Formulation / Manufacturing:see details

Pharmacology for NDA: 022272

Mechanism of ActionFull Opioid Agonists

Suppliers and Packaging for NDA: 022272

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
OXYCONTIN oxycodone hydrochloride TABLET, EXTENDED RELEASE;ORAL 022272 NDA AUTHORIZED GENERIC Teva Pharmaceuticals USA, Inc. 0093-5731 0093-5731-01 100 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (0093-5731-01)
OXYCONTIN oxycodone hydrochloride TABLET, EXTENDED RELEASE;ORAL 022272 NDA AUTHORIZED GENERIC Teva Pharmaceuticals USA, Inc. 0093-5732 0093-5732-01 100 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (0093-5732-01)

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET, EXTENDED RELEASE;ORALStrength10MG
Approval Date:Apr 5, 2010TE:RLD:Yes
Regulatory Exclusivity Expiration:Aug 13, 2018
Regulatory Exclusivity Use:NEW PATIENT POPULATION
Patent:► SubscribePatent Expiration:Jun 24, 2017Product Flag?YSubstance Flag?Delist Request?
Patent:► SubscribePatent Expiration:Mar 30, 2025Product Flag?YSubstance Flag?Delist Request?Y

Expired Orange Book Patents for NDA: 022272

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Purdue Pharma LpOXYCONTINoxycodone hydrochlorideTABLET, EXTENDED RELEASE;ORAL022272-001Apr 5, 2010► Subscribe► Subscribe
Purdue Pharma LpOXYCONTINoxycodone hydrochlorideTABLET, EXTENDED RELEASE;ORAL022272-006Apr 5, 2010► Subscribe► Subscribe
Purdue Pharma LpOXYCONTINoxycodone hydrochlorideTABLET, EXTENDED RELEASE;ORAL022272-006Apr 5, 2010► Subscribe► Subscribe
Purdue Pharma LpOXYCONTINoxycodone hydrochlorideTABLET, EXTENDED RELEASE;ORAL022272-002Apr 5, 2010► Subscribe► Subscribe
Purdue Pharma LpOXYCONTINoxycodone hydrochlorideTABLET, EXTENDED RELEASE;ORAL022272-003Apr 5, 2010► Subscribe► Subscribe
Purdue Pharma LpOXYCONTINoxycodone hydrochlorideTABLET, EXTENDED RELEASE;ORAL022272-003Apr 5, 2010► Subscribe► Subscribe
Purdue Pharma LpOXYCONTINoxycodone hydrochlorideTABLET, EXTENDED RELEASE;ORAL022272-007Apr 5, 2010► Subscribe► Subscribe
Purdue Pharma LpOXYCONTINoxycodone hydrochlorideTABLET, EXTENDED RELEASE;ORAL022272-002Apr 5, 2010► Subscribe► Subscribe
Purdue Pharma LpOXYCONTINoxycodone hydrochlorideTABLET, EXTENDED RELEASE;ORAL022272-005Apr 5, 2010► Subscribe► Subscribe
Purdue Pharma LpOXYCONTINoxycodone hydrochlorideTABLET, EXTENDED RELEASE;ORAL022272-007Apr 5, 2010► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.



Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Fuji
Johnson and Johnson
Daiichi Sankyo
Farmers Insurance
Novartis
QuintilesIMS
Cipla
Healthtrust
Argus Health
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot